СОВРЕМЕННЫЕ МЕТОДЫ ЛАБОРАТОРНОЙ ДИАГНОСТИКИРЕВМАТОИДНОГО АРТРИТА

1. <div><p>Насонов Е.Л. Современные направления иммунологических исследований при хронических воспалительных и аутоиммунных заболеваниях человека. Тер арх 2001;8:43-6.</p><p>Guidelines for immunologic laboratory testing in the rheumatic diseases: an introduction. American college of rheumatology ad hoc committee on immunologic testing guidelines. Arthritis Rheum 2002;47:429-33.</p><p>Насонов Е.Л., Александрова Е.Н. Современные стандарты лабораторной диагностики ревматических заболеваний. М., 2006; с. 3.</p><p>Wilk A.S., Gordon T.P., Kavanaugh A.F. et al. IUIS/WHO/AF/CDC Committee for the Standardization of Autoantibodies in Rheumatic and Related Diseases. Cutting edge diagnostics in rheumatology: the role of patients, clinicians, and laboratory scientists in optimizing the use of autoimmune serology. Arthritis Rheum 2004;51:291-8.</p><p>Кишкун А.А., Арсенин С.Л., Кольченко О.Л. Доказательная лабораторная медицина. Клин лаб диагност 2005;5:24-32.</p><p>Мошкин А.В., Долгов В.В. Обеспечение качества в клинической лабораторной диагностике. М.: Медиздат, 2004; 63-4.</p><p>Насонов Е.Л. Ранняя диагностика и фармакотерапия ревматоидного артрита: новые рекомендации для ревматологов и терапевтов. Врач 2002;9:3-7.</p><p>Kim J. M., Weisman M.H. When does rheumatoid arthritis begin and why do we need to know? Arthritis Rheum 2000;43(3):473-84.</p><p>Новиков А.А., Александрова Е.Н., Насонов Е.Л. Клиническое значение антител к циклическому цитруллинированному пептиду: новые данные. Клин мед 2007;85(8):4-9.</p><p>Новиков А.А., Александрова Е.Н., Каратеев Д.Е. и др. Диагностическое значение антител к модифицированному циклическому виментину при раннем ревматоидном артрите. Клин лаб диагност 2008;8:27-9.</p><p>Ursum J., Schaardenburg D., Nielen M. The value of antibodies to mutated citrullinated vimentin in early arthritis. Ann Rheum Dis 2007;66(Suppl. II):339.</p><p>Dejaco C., Klotz V., Larcher H. et al. Diagnostic value of antibodies against a modified citrullinated vimentin in rheumatoid arthritis. Arthritis Res Ther 2006;8(4):119-25.</p><p>Bang H., Luthke K., Gauliard A. et al. Mutated citrullinated vimentin (MCV) as a candidate autoantigen for diagnosis and monitoring of disease activity in rheumatoid arthritis. Ann Rheum Dis 2006;65(Suppl. II):144.</p><p>Rheumatoid arthritis, Oxford University press, 2006; p. 193-7.</p><p>Nienhius R.L.F., Maudema E.A. A new serum factor in patients with rheumatoid arthritis. The antiperinuclear factor. Ann Rheum Dis 1964;23:302-5.</p><p>Насонов Е.Л., Штутман В.З., Сперанский А.И. Антиперинуклеарный фактор и антитела к кератину: новые серологические маркеры ревматоидного артрита. Клин ревматол 1993;2:20-4.</p><p>Hoet R.M., van Venrooij W.J. The antiperinuclear factor and antikeratin antibodies in rheumatoid arthritis. Springer Verlag, In Rheumatoid Arthritis 1992;299-318.</p><p>Despres N., Boire G., Lopez-Longo F.J. et al. The Sa system: a novel antigen-antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-33.</p><p>Hueber W., Hassfeld W., Smolen J.S. et al. Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology 1999;38:155-9.</p><p>Goldbach-Mansky R., Lee J., Mc Coy A. et al. Rheumatoid arthritis associated аutoantibodies in patients with synovitis of recent onset. Arthritis Res 2000;2:236-43.</p><p>Escalona M., Lopez-Longo F.J., Gonzalez C.M. et al. Anti-Sa sera from patients with rheumatoid arthritis contain at least 2 different subpopulations of anti-Sa antibodies. J Rheumatol 2002;29:2053-60.</p><p>Hayem G., Chazerain P., Combe B. et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999;26:7-13.</p><p>Young B.J., Mallya R.K., Leslie R.D. et al. Anti-keratin antibodies in rheumatoid arthritis. Br Med J 1979;2:97-9.</p><p>Dubucquoi S., Solau-Gervais E., Lefranc D. et al. Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases. Ann Rheum Dis 2004;63:415-9.</p><p>Bodman-Smith M., Corrigall V., Berglin E. et al. Antibody response to the human stress protein BiP in rheumatoid arthritis. Rheumatology (Oxford) 2004;43:1283-7.</p><p>Van der Cruyssen B., Cantaert T., Nogueira L. et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 2006;8(4):122-9.</p><p>Blaeb S., Specker C., Lacomec H. et al. Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann Rheum Dis 1995;54:355-60.</p><p>Mimori T., Suganuma K., Tanami Y. et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995;92:7267-71.</p><p>Saulot V., Vittecoq O., Charlionet R. et al. Presence of autoantibodies to the glycolytic enzyme-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 2002;46(5):1196-201.</p><p>Vincent C., Keyser F., Masson C. et al. Anti-perinuclear factor compared with the so called "antikeratin" antibodies and antibodies to human epidermis filaggrin, in the diagnosis of arthritides. Ann Rheum Dis 1999;58:42-8.</p><p>Meyer О., Labarre С., Dougados М. et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.</p><p>Shmerling R.H., Delbanco T.L. The rheumatoid factor: an analysis of clinical utility. Am J Med 1991;91:528-34.</p><p>Waaler E. On the occurance of factoring human serum activating the specific agglutination of sheep blood carpuscule. Acta Pathol Microbiol Immunol Scand 1939;17:172-82.</p><p>Tigh H., Carson D. Rheumatoid factor. Textbook of rheumatology. Philadelphia, WB Saunders 1997; p. 241-9.</p><p>Arnett F.C., Edworthy S.M., Bloch D.A. et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.</p><p>Hueber W., Utz P.J., Robinson W.H. Autoantibodies in early arthritis: advances in diagnosis and prognostication. Clin Exp Rheumatol 2003;21(Suppl. 31):59-64.</p><p>Jansen A., van der Horst-Bruinsma I., van Shaardenbzrg D. et al. Rheumatoid factor and antibodies to ciclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 2002;29:2074-6.</p><p>Nell V., Machold K., Eberl G. et al. The diagnostic and prognostic significance of autoantibodies in patients with early arthritis. Ann Rheum Dis 2003;2(1):69.</p><p>Sinclair D., Hull D.G. Why do general practitionares request rheumatoid factor? A study of symptoms, requesting patterns and patients outcomes. Ann Clin Biochem 2003;30(2):131-7.</p><p>Ревматология: национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; с. 50-1.</p><p>Houssien D., Jonsson T., Davies E. et al. Clinical significanse of IgA rheumatoid factor subclasses in rheumatoid arthritis. J Rheumatol 1997;24:2119-22.</p><p>Vencovsky J., Machacek S., Sedova L. et al. Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Ann Rheum Dis 2003;62:427-30.</p><p>Vossenaar E., Nijenhuis S., Helsen M. et al.</p><p>Makrygiannakis D., Klint E., Lundberg I. et al. Citrullination is an inflammation-dependent process. Ann Rheum Dis 2006;65:1219-22.</p><p>Menard H., Lapointe E., Rochdi M. et al. Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Res 2000;2:429-32.</p><p>Masson-Bessiere C., Sebbag M., Girbal-Neuhauser E. et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantobodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166:4177-84.</p><p>Bobbio-Pallavicini F., Caporali R., Alpini C. et al. Predictive value of antibodies to citrullinated peptides and rheumatoid factors in anti-TNF-alpha treated patients. Ann N Y Acad Sci 2007;1109:287-95.</p><p>Schellekens G., Visser H., de Jong B. et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.</p><p>Vossenaar E.R., Despres N., Lapointe E. et al. Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Res Ther 2004;6:142-50.</p><p>Schellekens G.A., de Jong B.A., van den Hoogen F.H. et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101(1):273-81.</p><p>El-Gabalawy H.S., Wilkins J.A. Anti-Sa antibodies: prognostic and pathogenetic significance to rheumatoid arthritis. Arthritis Res Ther 2004;6:86-9.</p><p>Vossenaar E.R., Smeets T.J., Kraan M.C. et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum 2004;50(11):3485-94.</p><p>Hill A.J., Southwood S., Sette A. et al. Cutting edge: the conversation of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003;17:538-41.</p><p>Schur P. Anti-cyclic citrullinated peptide antibodies: diagnostic, predictive, and monitoring value in RA. Int J Adv Rheumatol 2005;3(3):77-83.</p><p>Suzuki A., Yamada R., Chang X. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003;34:395-402.</p><p>Genevay S., Hauem G., Verpillat P. et al. An eight year prospective study of outcome prediction by antiperinuclear factor and antikeratin antibodies at onset of rheumatoid arthritis. Ann Rheum Dis 2002;6:734-6.</p><p>Serre G., Vincent C. Filaggrin (keratin) autoantibodies. In: Autoantibodies. Amsterdam, London, New York 1996; 271-6.</p><p>Vincent C., Simon M., Sebbag M. et al.</p><p>Pamela L., Palosio T., Aho K. et al. Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis 2001;60:32-5.</p><p>Avouac J., Gossec L., Dougados M. Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis 2006;65:845-51.</p><p>Lоpez-Longo F., Rodriguez-Mahou M., Sanchez-Ramon S. et al. Anti-Cyclic Citrullinated Peptide versus Anti-Sa Antibodies in Diagnosis of Rheumatoid Arthritis in an Outpatient Clinic for Connective Tissue Disease and Spondyloarthritis. J Rheumatol 2006;33:1476-81.</p><p>Александрова Е.Н., Чемерис Н.А.,Каратеев Д.Е. и др. Антитела к циклическому цитруллинированному пептиду при ревматоидном атрите. Тер арх 2004;12:64-8.</p><p>Coenen D., Verschueren P., Westhovens R. et al. Technical and diagnostic performance of 6 assays for the measurement of citrullinated protein/peptide antibodies in the diagnosis of rheumatoid arthritis. Clin Chem 2007;53(3):498-504.</p><p>Szekanecz Z., Tumpek J., Szabo Z. et al. The INOVA CCP3.1 IGA/IGG ELISA represents significant improvement in the laboratory diagnosis of rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):568.</p><p>Nijenhuis S., Zendman A., Vossenaar E. et al. Autoantibodies to citrullinated proteins in rheumatoid arthritis: clinical performance and biochemical aspects of an RA-specific marker. Clin Chim Acta 2004;350:17-34.</p><p>Lee D.M., Schur P.H. Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Ann Rheum Dis 2003;62:870-4.</p><p>Suzuki K., Sawada T., Murakami A. et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003;32:197-204.</p><p>Nell V.P., Machold K.P., Stamm T.A. et al. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis 2005;64:1731-6.</p><p>Bizzaro N., Mazzanti G., Tonutti E. et al. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.</p><p>Bas S., Genevay S., Meyer O., Gabay C. Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology (Oxford) 2003;42(5):677-80.</p><p>Lakos G., Soos L., Fekete A. et al. Anticiclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope. Ann Rheum Dis 2008;67(Suppl. II):569.</p><p>Verport K.R., Jol-van der Zijde C.M., Papendrecht-van der Voort E.A. et al. Isotype distribution of anti-ciclic citrullinated peptides antibodies in undifferentiated arthritis and rheumatoid arthritis reflects an ongoing immune response. Arthritis Rheum 2006;54:3799-808.</p><p>Salvador G., Gomez A., Vinas O. et al. Prevalence and clinical significance of anticyclic citrullinated peptide and antikeratin antibodies in palindromic rheumatism. An abortive form of rheumatoid arthritis? Rheumatology 2003;42:972-5.</p><p>Mediwake R., Isenberg D.A., Schellekens G.A. et al. Use of anticitrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 2001;60:67-8.</p><p>van Rossum M., van Soesbergen R., de Kort S. et al. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. J Rheumatol 2003;30(4):825-8.</p><p>Low J.M., Chauhan A.K., Kietz D.A. et al. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol 2004;31(9):1829-33.</p><p>Avcin T., Cimaz R., Falcini F. et al. Prevalence and clinical significance of anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Ann Rheum Dis 2002;61(7):608-11.</p><p>Bombardieri M., Alessandri C., Labbadia G. et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement. Arthritis Res Ther 2004;6(2):137-41.</p><p>van Gaalen F.A., Linn-Rasker S.P., van Venrooij W.J. et al. Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study. Arthritis Rheum 2004;50:709-15.</p><p>Rantapaa-Dahlqvist S., de Jong B., Berglin E. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.</p><p>Nielen M., van Schaardenburg D., Reesink H. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-6.</p><p>Riedemann J., Munoz S., Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis - a systematic review. Clin Exp Rheumatol 2005;2:69-76.</p><p>Berglin E., Padyukov L., Sundin U. et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLADRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:303-8.</p><p>Zeng X., Ai M., Tian X. et al. Diagnostic 43 value of anticyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003;30:1451-5.</p><p>Niewold T., Harrison M., Paget S. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. Q J Med 2007;100:193-201.</p><p>Novikov A.A., Alexandrova E.N., Karateev D.E. et al. Diagnostic value of antibodies against a modified citrullinated vimentin, cyclic citrullinated peptide and IgM rheumatoid factor in early rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl. II):333.</p><p>Forslind K., Ahlmen M., Eberhardt K. et al. Prediction of radiological outcome in early RA in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63:1090-5.</p><p>Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during three years in early rheumatoid arthritis (the TIRA project). Ann Rheum Dis 2004;63:1085-9.</p><p>Zendman A., van Venrooij W., Pruijn G. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 2006;45:20-5.</p><p>de Rycke L., Peene I., Hoffman I. et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extraarticular manifestations. Ann Rheum Dis 2004;63:1587-93.</p><p>Ota F., Maeshima A., Yamashita S. et al. Activin A induces cell proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 2003;48:2442-9.</p><p>Marinova-Mutafchieva L., Taylor P., Funa K. et al. Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum 2000;43:2046-55.</p><p>Xue C., Takahashi M., Hasunuma T. et al. Characterisation of fibroblast-like cells in pannus lesions of patients with rheumatoid arthritis sharing properties of fibroblasts and chondrocytes. Ann Rheum Dis 1997;56:262-7.</p><p>Vossenaar E.R., Radstake T.R., van der Heijden A. et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004;63:373-81.</p><p>Bang H., Egerer K., Gauliard A. et al. Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 2007;56:2503-11.</p><p>Zimmermann C., Hoefler E., Steiner G. Diagnostic value of anti-CCP and anti-mutated citrullinated vimentin (MCV) testing in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):149.</p><p>Matsson L., Mullazehi M., Wick M. et al. Antibodies against citrullinated vimentin in rheumatoid arthritis. Arthritis Rheum 2008;58:36-45.</p><p>Boire G., Gosette P., Combe B. et al. Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset polyarthritis. Arthritis Res Ther 2005;7:529-603.</p><p>Rodrigues-Mahou M., Lopez-Longo F.,Sanchez-Ramon S. et al. Association of Anti-Cyclic Citrullinated Peptide and Anti-Sa/Citrullinated Vimentin Autoantibodies in Rheumatoid Arthritis. Arthritis Rheum (Arthritis Care &amp; Res) 2006;55(4):657-61.</p><p>Nielen M., van der Horst A., van Schaardenburg D. et al. Antibodies to citrullinated human fibrinogen (ACF) arthritis have diagnostic and prognostic value in early. Ann Rheum Dis 2005;64:1199-204.</p><p>Steiner G., Hartmuth K., Skriner K. Purification and patial sequensing of the nuclear autoantigen RA33 shows that it is indistinguishable from A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest 1992;90:1061-6.</p><p>Hassfeld W., Streiner G., Graninger W. et al. Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.</p><p>Hassfeld W., Steiner G., Studnicka-Benke A. et al. Autoimmune response to the spliceosome: an immunological link between rheumatoid arthritis, mixed connective tissue disease and systemic lupus erythematosus. Arthritis Rheum 1995;38:777-85.</p><p>Meyer O., Tauxe F., Fabregas D. et al. Anti-RA33 antinuclear antibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 1993;11:473-8.</p><p>Sasso E.N. Immunoglobulin V genes in rheumatoid arthritis. Rheum Dis Clin North Am 1992;18:809-36.</p><p>Cordonnier C., Meyer O., Palazzo E. et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, perinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.</p><p>Blaeb S., Union S., Raymackers J. et al. The stress protein BiP is overexpressed and is a major B- and T-cell target in rheumatoid arthritis. Arthritis Rheum 2001;44:971-80.</p><p>Matsumoto I., Straub A., Benoist C. et al. Arthritis provoked by linked T and B cell recognition of a glycolytic enzime. Sceince 1999;286:1732-5.</p><p>Corrigall V., Bodman-Smith M., Brunst M. et al. Ingibition of antign-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an anti-inflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis. Arthritis Rheum 2004;50:1164-71.</p><p>Насонов Е.Л., Баранов А.А., Шилкина Н.П. Васкулиты и васкулопатии. Ярославль, 1999;48 с.</p><p>Sox H.C., Liang M.H. The erythrocyte sedimentation rate. Guidelines for rational use. Ann Intern Med 1986;104:515-23.</p><p>Brigden M. The erythrocyte sedimentation rate. Still a helpful test when used judiciously. Postgrad Med 1998;103:257-74.</p><p>Myklebust G., Gran J.T. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol 1996;35:1161-8.</p><p>Gonzalez-Gay M., Rodriguez-Valverde V., Blanco R. et al. Polymyalgia rheumatica without significantly increased erythrocyte sedimentation rate. A more benign syndrome. Arch Intern Med 1997;157:317-20.</p><p>Miller A., Green M., Robinson D. Simple rule for calculating normal erythrocyte edimentation rate. Br Med J (Clin Res Ed) 1983;286:266.</p><p>Pepys M.B., Baltz M.L. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol 1983;34:141-212.</p><p>Vigushin D.M., Pepys M.B., Hawkins P.N. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7.</p><p>Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999;138:419-20.</p><p>Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок -маркер воспаления при атеросклерозе (новые данные). Кардиология 2002;7:53-62.</p><p>Libby P., Ridker P., Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-43.</p><p>Ridker P., Cushman M., Stampfer M. et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.</p><p>Ridker P.M., Hennekens C.H., Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-43.</p><p>Ridker P.M. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9.</p><p>Pepys M.B., Hirschfield G.M. C-reactive protein: a critical update. J Clin Invest 2003;111:1805-12.</p><p>Scott D.L. Radiological progression in established rheumatoid arthritis. J Rheumatol 2004;69(Suppl.):55-65.</p><p>Wells G., Becker J., Teng J. et al. Validation of the Disease Activity Score 28 (DAS28) disease progression in patients with rheumatoid and EULAR response criteria based on CRP against arthritis, and comparison with the DAS28 based on ESR. Ann Rheum Dis 2009;68(6):954-60.</p><p>Ridker P.M. Cardiology Patient Page. C-reactive protein: a simple test to help predict risk of heart attack and stroke.</p><p>Gonzalez-Gay M.A., Gonzalez-Juanatey C., Pineiro A. et al. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005;32:1219-23.</p><p>Barnes E.V., Narain S., Naranjo A. et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005;14:576-82.</p><p>Malle E., De Beer F. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-35.</p><p>Tam S., Flexman A., Hulme J. et al. Promoting export of macrophage cholesterol: the physiological role of a major acutephase protein, serum amyloid A. J Lipid Res 2002;43:1410-20.</p><p>Thorn C.F., Lu Z.Y., Witehead A.S. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand J Immunol 2004;59:152-8.</p><p>Mullan R., Breshnikan B., Golden-Mason L. et al. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum 2006;54:105-14.</p><p>Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389:39-48.</p><p>Dayer E., Dayer J., Roux-Lombard P. Primer: the practical use of biological markers of rheumatic and systemic inflammatory diseases. Nat Clin Pract Rheumatol 2007;3(9):512-20.</p><p>Cunnane G., Grehan S., Geoghegan S. et al. Serum amyloid A in the assessment of early inflammatory arthritis. J Rheumatol 2000;27:58-63.</p><p>Gillmore J.D., Lovat L.B., Persey M.R. et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9.</p><p>Chambers R., Macfarlane D., Whicher J. et al. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann Rheum Dis 1983;42:665-7.</p><p>Назаренко Г.И., Кишкун А.А. Клиническая оценка результатов лабораторных исследований. М.: Медицина, 2000;261 с.</p><p>Bach R., Gormsen J. Fibrinolytic and fibrin stabilizing activity of synovial membranes. Ann Rheum Dis 1976;29:287-93.</p><p>Flick M., Jeunesse C., Talmage K. et al. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin αMβ2 binding motif. J Clin Invest 2007;117:3224-35.</p><p>Ribbens C., Andre B., Kaye O. et al. Synovial fluid matrix metalloproteinase 3 levels are increased in inflammatory arthritis whether erosive or not. Rheumatology 2000;39:1357-65.</p><p>Posthumus M., Limburg P., Westra J. et al. Serum matrix metalloproteinase 3 levels in comparison to C-reactive protein in periods with and without progression of radiological damage in patients with early rheumatoid arthritis. Clin Exp Rheum 2003;21:465-72.</p><p>Alessandri C., Bombardieri M., Papa N. et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004;63:1218-21.</p><p>Atzeni F., Puttini P., Dell'Acqua D. et al. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. Arthritis Res Ther 2006;8:3.</p><p>Bos W., Bartelds G., de Koning M. et al. Decrease in rheumatoid factor and anti-citrullinated protein antibody levels is associated with response to adalimumab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):74.</p><p>Grosjean C., de Chaisemartin L., Nicaise-Roland P. et al. Prospective cohort study of rituximab effects on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):196.</p><p>Sato E., Inoue E., Shidara K. et al. Usefulness of MCV as a marker for disease activity as well as a predicting factor for the efficacy of infliximab treatment in a large observational cohort of japanese RA patients. Ann Rheum Dis 2008;67(Suppl. II):313.</p><p>Chu Miow Lin D., Ducourau E., Mulleman D. et al. Infliximab concentration is predictive of control of disease activity and maintenance of treatment in rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):177.</p><p>Mikuls T.R., O'Dell J.R., Stoner J.A. et al. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. Arthritis Rheum 2004;50:3776-82.</p><p>Ronnelid J., Wick M., Lampa J. et al. Longitudinal analysis of anti-citrullinated protein/peptide antibodies (anti-CP) during 5 year follow-up in early rheumatoid arthritis: anti-CP status is a stable phenotype that predicts worse disease activity and greater radiological progression. Ann Rheum Dis 2005;64(12):1744-9.</p><p>Triantafyllou A., Pyrpasopoulou A., Anyfanti P. et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with active inflammatory disease. Ann Rheum Dis 2008;67(Suppl. II):333.</p><p>Bobbio-Pallavicini F., Alpini C., Caporali R. et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. Arthritis Res Ther 2004;6:264-72.</p><p>Caramaschi P., Biasi D., Tonolli E. et al. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatol Int 2005;26(1):58-62.</p><p>Nissinen R., Leirisalo-Repo M., Peltomaa R. et al. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis 2004;63:681-7.</p><p>Klareskog L., Moreland L., Cohen S. et al. Safety and efficacy of over 10 years of continuous etanercept therapy in patients with rheumatoid arthritis in North America and Europe. Ann Rheum Dis 2008;67(Suppl. II):175.</p><p>Chen H., Lin K., Chen C. et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Ann Rheum Dis 2006;65:35-9.</p><p>Blank N., Max R., Briem S. et al. Combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):188.</p><p>Jones G., Gu J., Lowenstein M. et al. Tocilizumab monotherapy is superior to methotrexate monotherapy in reducing disease activity in patients with rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2008;67(Suppl. II):89.</p><p>Levi M., Frey N., Grange S. et al. Reduction in inflammatory biomarkers with increasing exposure to the IL-6 inhibitor, tocilizumab, in patients with rheumatoid arthritis: graphical analysis of pooled data. Ann Rheum Dis 2008;7(Suppl. II):192.</p><p>Beaulieu А., McKay J., Pavelka K. et al. Treatment with the humanized anti-interleukin-6 receptor antibody tocilizumab results in rapid improvements in the signs and symptoms of rheumatoid arthritis: results from a pooled analysis of clinical trial data from option and toward. Ann Rheum Dis 2008;67(Suppl. II):195.</p><p>Garnero P., Mareau E., Thompson E. Тhe anti-IL-6 receptor inhibitor tocilizumab (TCZ) combined with methotrexate (MTX) has beneficial effects on bone and cartilage metabolism in patients with rheumatoid arthritis (RA): results of a phase III 24 week randomized placebo controlled study. Ann Rheum Dis 2008;67(Suppl. II):193.</p></div><br />